Jaguar Health (JAGX)
Market Price (10/31/2026): $1.6 | Market Cap: $3.7 MilSector: Health Care | Industry: Biotechnology
Jaguar Health (JAGX)
Market Price (10/31/2026): $1.6Market Cap: $3.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -185% | High stock price volatilityVol 12M is 1209% Key risksJAGX key risks include [1] substantial "going concern" risk due to severe financial instability, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -185% |
| High stock price volatilityVol 12M is 1209% |
| Key risksJAGX key risks include [1] substantial "going concern" risk due to severe financial instability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/30/2026
Jaguar Health (JAGX) stock has lost about 95% since 6/30/2026 because of the following key factors:
1. Severe Stock Dilution and Capital Structure Overhang.
Jaguar Health has undertaken multiple actions since fiscal Q2 2026 that have significantly diluted shareholders and created substantial uncertainty around its capital structure. In June 2026, the company established an equity line of credit of up to $40 million, providing capital but posing ongoing dilution risk through the issuance of new common stock. This was compounded by further dilution from debt-for-equity exchanges, with the potential for over 112 million common shares to be issued if Series Q Preferred Stock converts at a low price point. Additionally, in October 2026, Jaguar Health announced a special stock dividend of Series R Convertible Preferred Stock, which is set to convert into common shares at a ratio of five common shares per preferred share in November 2026, further increasing the outstanding share count. The company's history of eight reverse stock splits since 2018 highlights a persistent reliance on dilutive financing to maintain operations.
2. Persistent Poor Financial Performance and Going Concern Doubts.
Jaguar Health continues to grapple with significant financial distress, reporting recurring losses and negative cash flow. For fiscal Q2 2026, the company recorded a net loss of approximately $12.7 million on revenues of about $1.2 million, representing a 59.7% year-over-year drop in product revenue from fiscal Q2 2025. As of March 31, 2026, the accumulated deficit stood at approximately $391.1 million. These sustained losses and the substantial accumulated deficit have led to disclosures of "substantial doubt about its ability to continue as a going concern," severely undermining investor confidence and contributing to the stock's decline. The company's weak financial fundamentals are also evidenced by a low current ratio of 0.69 and a high debt-to-equity ratio of 2.77 as of October 2026, indicating significant liquidity and solvency concerns.
Show more
Jaguar Health (JAGX) stock has lost about 95% since 6/30/2026 because of the following key factors:
1. Severe Stock Dilution and Capital Structure Overhang.
Jaguar Health has undertaken multiple actions since fiscal Q2 2026 that have significantly diluted shareholders and created substantial uncertainty around its capital structure. In June 2026, the company established an equity line of credit of up to $40 million, providing capital but posing ongoing dilution risk through the issuance of new common stock. This was compounded by further dilution from debt-for-equity exchanges, with the potential for over 112 million common shares to be issued if Series Q Preferred Stock converts at a low price point. Additionally, in October 2026, Jaguar Health announced a special stock dividend of Series R Convertible Preferred Stock, which is set to convert into common shares at a ratio of five common shares per preferred share in November 2026, further increasing the outstanding share count. The company's history of eight reverse stock splits since 2018 highlights a persistent reliance on dilutive financing to maintain operations.
2. Persistent Poor Financial Performance and Going Concern Doubts.
Jaguar Health continues to grapple with significant financial distress, reporting recurring losses and negative cash flow. For fiscal Q2 2026, the company recorded a net loss of approximately $12.7 million on revenues of about $1.2 million, representing a 59.7% year-over-year drop in product revenue from fiscal Q2 2025. As of March 31, 2026, the accumulated deficit stood at approximately $391.1 million. These sustained losses and the substantial accumulated deficit have led to disclosures of "substantial doubt about its ability to continue as a going concern," severely undermining investor confidence and contributing to the stock's decline. The company's weak financial fundamentals are also evidenced by a low current ratio of 0.69 and a high debt-to-equity ratio of 2.77 as of October 2026, indicating significant liquidity and solvency concerns.
Show more
Updated on 10/30/2026
Jaguar Health (JAGX) stock has lost about 95% since 6/30/2026 because of the following key factors:
1. Severe Stock Dilution and Capital Structure Overhang.
Jaguar Health has undertaken multiple actions since fiscal Q2 2026 that have significantly diluted shareholders and created substantial uncertainty around its capital structure. In June 2026, the company established an equity line of credit of up to $40 million, providing capital but posing ongoing dilution risk through the issuance of new common stock. This was compounded by further dilution from debt-for-equity exchanges, with the potential for over 112 million common shares to be issued if Series Q Preferred Stock converts at a low price point. Additionally, in October 2026, Jaguar Health announced a special stock dividend of Series R Convertible Preferred Stock, which is set to convert into common shares at a ratio of five common shares per preferred share in November 2026, further increasing the outstanding share count. The company's history of eight reverse stock splits since 2018 highlights a persistent reliance on dilutive financing to maintain operations.
2. Persistent Poor Financial Performance and Going Concern Doubts.
Jaguar Health continues to grapple with significant financial distress, reporting recurring losses and negative cash flow. For fiscal Q2 2026, the company recorded a net loss of approximately $12.7 million on revenues of about $1.2 million, representing a 59.7% year-over-year drop in product revenue from fiscal Q2 2025. As of March 31, 2026, the accumulated deficit stood at approximately $391.1 million. These sustained losses and the substantial accumulated deficit have led to disclosures of "substantial doubt about its ability to continue as a going concern," severely undermining investor confidence and contributing to the stock's decline. The company's weak financial fundamentals are also evidenced by a low current ratio of 0.69 and a high debt-to-equity ratio of 2.77 as of October 2026, indicating significant liquidity and solvency concerns.
3. Nasdaq Listing Non-Compliance and Reverse Stock Split.
To address non-compliance with Nasdaq's minimum bid price requirement, Jaguar Health implemented a 1-for-15 reverse stock split, effective September 17, 2026. While intended to regain compliance, reverse stock splits often fail to address underlying operational issues and are frequently perceived negatively by the market, signaling desperation and often preceding further share price declines. The significant drop in stock value following this corporate action suggests that the reverse split did not restore investor confidence in the company's ability to maintain its listing or improve its financial viability.
Show less
Jaguar Health (JAGX) stock has lost about 95% since 6/30/2026 because of the following key factors:
1. Severe Stock Dilution and Capital Structure Overhang.
Jaguar Health has undertaken multiple actions since fiscal Q2 2026 that have significantly diluted shareholders and created substantial uncertainty around its capital structure. In June 2026, the company established an equity line of credit of up to $40 million, providing capital but posing ongoing dilution risk through the issuance of new common stock. This was compounded by further dilution from debt-for-equity exchanges, with the potential for over 112 million common shares to be issued if Series Q Preferred Stock converts at a low price point. Additionally, in October 2026, Jaguar Health announced a special stock dividend of Series R Convertible Preferred Stock, which is set to convert into common shares at a ratio of five common shares per preferred share in November 2026, further increasing the outstanding share count. The company's history of eight reverse stock splits since 2018 highlights a persistent reliance on dilutive financing to maintain operations.
2. Persistent Poor Financial Performance and Going Concern Doubts.
Jaguar Health continues to grapple with significant financial distress, reporting recurring losses and negative cash flow. For fiscal Q2 2026, the company recorded a net loss of approximately $12.7 million on revenues of about $1.2 million, representing a 59.7% year-over-year drop in product revenue from fiscal Q2 2025. As of March 31, 2026, the accumulated deficit stood at approximately $391.1 million. These sustained losses and the substantial accumulated deficit have led to disclosures of "substantial doubt about its ability to continue as a going concern," severely undermining investor confidence and contributing to the stock's decline. The company's weak financial fundamentals are also evidenced by a low current ratio of 0.69 and a high debt-to-equity ratio of 2.77 as of October 2026, indicating significant liquidity and solvency concerns.
3. Nasdaq Listing Non-Compliance and Reverse Stock Split.
To address non-compliance with Nasdaq's minimum bid price requirement, Jaguar Health implemented a 1-for-15 reverse stock split, effective September 17, 2026. While intended to regain compliance, reverse stock splits often fail to address underlying operational issues and are frequently perceived negatively by the market, signaling desperation and often preceding further share price declines. The significant drop in stock value following this corporate action suggests that the reverse split did not restore investor confidence in the company's ability to maintain its listing or improve its financial viability.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
nullnull
Market Drivers
6/30/2026 to 10/30/2026| Return | Correlation | |
|---|---|---|
| JAGX | -96.4% | |
| Market (SPY) | 1.2% | 2.8% |
| Sector (XLV) | 16.5% | 4.4% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2026 to 10/30/2026| Return | Correlation | |
|---|---|---|
| JAGX | -99.2% | |
| Market (SPY) | 16.5% | 1.7% |
| Sector (XLV) | 26.7% | 3.8% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2025 to 10/30/2026| Return | Correlation | |
|---|---|---|
| JAGX | -99.9% | |
| Market (SPY) | 14.4% | 3.5% |
| Sector (XLV) | 34.5% | 3.8% |
Fundamental Drivers
nullnull
Market Drivers
9/30/2023 to 10/30/2026| Return | Correlation | |
|---|---|---|
| JAGX | -100.0% | |
| Market (SPY) | 82.9% | 4.0% |
| Sector (XLV) | 50.4% | 4.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| JAGX Return | -58% | -92% | -98% | -89% | -96% | -100% | -100% |
| Peers Return | 18% | 23% | 15% | 2% | 24% | 33% | 179% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| JAGX Win Rate | 17% | 8% | 33% | 25% | 17% | 10% | |
| Peers Win Rate | 55% | 55% | 53% | 57% | 63% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| JAGX Max Drawdown | -91% | -92% | -98% | -95% | -97% | -100% | |
| Peers Max Drawdown | -18% | -20% | -17% | -27% | -24% | -19% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ABBV, AMGN, GILD, REGN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/30/2026 (YTD)
How Low Can It Go
| Event | JAGX | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -44.4% | -33.7% |
| % Gain to Breakeven | 79.9% | 50.9% |
| Time to Breakeven | 120 days | 140 days |
In The Past
Jaguar Health's stock fell -44.4% during the 2020 COVID-19 Crash. Such a loss loss requires a 79.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | JAGX | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -44.4% | -33.7% |
| % Gain to Breakeven | 79.9% | 50.9% |
| Time to Breakeven | 120 days | 140 days |
In The Past
Jaguar Health's stock fell -44.4% during the 2020 COVID-19 Crash. Such a loss loss requires a 79.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Jaguar Health (JAGX)
Jaguar Health, Inc. (JAGX) is a commercial-stage pharmaceutical company focused on developing and commercializing prescription medicines for gastrointestinal distress. Specifically, the company targets chronic and debilitating diarrhea in both human and animal patients. Operating through distinct Human Health and Animal Health segments, Jaguar Health aims to provide therapeutic solutions for a variety of diarrheal conditions.
In its Human Health segment, Jaguar Health's primary commercialized product is Mytesi. This medication offers symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS who are undergoing antiretroviral therapy. The company is also actively developing Crofelemer for multiple potential follow-on indications, including diarrhea associated with cancer therapy, rare congenital diarrheal disorders in children, short bowel syndrome, supportive care for inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome, and idiopathic/functional diarrhea. Additionally, Jaguar Health is advancing lechlemer, a second-generation anti-secretory agent, for the treatment of cholera.
For its Animal Health segment, Jaguar Health is developing Canalevia, an oral plant-based drug candidate. This product is designed to treat specific conditions in dogs, namely chemotherapy-induced diarrhea and exercise-induced diarrhea, addressing unmet needs in veterinary care.
AI Analysis | Feedback
Here are 1-3 brief analogies for Jaguar Health (JAGX):
Imagine a **Gilead Sciences** but exclusively focused on developing prescription drugs for chronic diarrhea in both humans and animals.
Think of them as a **Takeda Pharmaceutical Company** (known for its GI focus) that also develops prescription medications for diarrhea in companion animals.
AI Analysis | Feedback
- Mytesi: A prescription medicine for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Crofelemer: A drug candidate being developed for multiple possible follow-on indications, including cancer therapy-related diarrhea and orphan-drug indications.
- Lechlemer: A second-generation anti-secretory agent in development for cholera.
- Canalevia: An oral plant-based drug candidate to treat chemotherapy-induced diarrhea and exercise-induced diarrhea in dogs.
AI Analysis | Feedback
null
AI Analysis | Feedback
- Glenmark Life Sciences Ltd. (GLENMARK)
- Thermo Fisher Scientific Inc. (TMO)
AI Analysis | Feedback
Lisa Conte, Chief Executive Officer and President
Lisa Conte is the founder, President, and Chief Executive Officer of Jaguar Health, appointed to her CEO role in June 2013. She has pioneered plant-based prescription medicine investigation and development for over 30 years. Prior to Jaguar Health, Ms. Conte founded Napo Pharmaceuticals and Shaman Pharmaceuticals in 1989. After facing challenges with Shaman Pharmaceuticals, she transitioned it into a dietary supplement business before founding Napo Pharmaceuticals, which acquired Shaman's intellectual property in 2001. Jaguar Animal Health, a company she also led, was spun out of Napo and later merged with Napo Pharmaceuticals in July 2017 to form the current Jaguar Health. Her career began as a venture capitalist, and she has raised significant funding from a mix of venture capital, angel investors, and high-net-worth individuals for her ventures.
Carol Lizak, Chief Financial Officer
Carol Lizak was promoted to Chief Financial Officer of Jaguar Health in April 2021, having initially joined the company in May 2019. Before her promotion, she served as Senior Vice President of Finance and Chief Accounting Officer at Jaguar. Ms. Lizak brings over 20 years of experience in corporate controllership and financial planning and analysis. Her prior roles include Senior Director and Corporate Controller of Zosano Pharma Corporation, Controller of Quantum Secure, Inc., Executive Director, Corporate Controller of Alexza Pharmaceuticals, Inc., and Corporate Controller for nine years at a subsidiary of HID Global Corporation. She holds an MBA from Pepperdine Graziadio Business School.
Jonathan Wolin, Chief of Staff, General Counsel and Chief Compliance Officer
Jonathan Wolin serves as Jaguar Health's Chief of Staff, General Counsel, and Chief Compliance Officer.
Pravin Chaturvedi, Chief Scientific Officer
Pravin Chaturvedi is the Chief Scientific Officer at Jaguar Health.
Steven King, Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property; Secretary
Steven King holds the titles of Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property, and Secretary at Jaguar Health.
AI Analysis | Feedback
Key Risks to Jaguar Health (JAGX):
- Reliance on Successful Clinical Development, Regulatory Approval, and Commercialization of Pipeline Products: Jaguar Health's future growth and profitability are heavily dependent on the successful development and commercialization of its pipeline drug candidates, including Crofelemer (for various indications such as cancer therapy-related diarrhea, congenital diarrheal disorders, short bowel syndrome, inflammatory bowel diseases, irritable bowel syndrome, and idiopathic/functional diarrhea), lechlemer for cholera, and Canalevia for dogs. The drug development process is inherently uncertain, lengthy, and expensive, with a high risk of failure in clinical trials or challenges in obtaining regulatory approvals. Even if approved, these products must gain market acceptance against potential competitors.
- Limited Revenue Stream and Market Penetration of Mytesi: The company currently markets Mytesi as its sole prescription product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar Health's current financial performance and ability to fund its extensive pipeline are significantly reliant on Mytesi's continued commercial success and market penetration. Any issues impacting Mytesi, such as increased competition, safety concerns, market acceptance challenges, or pricing pressures, could have a material adverse effect on the company.
AI Analysis | Feedback
null
AI Analysis | Feedback
Jaguar Health (symbol: JAGX) focuses on developing prescription medicines for gastrointestinal distress in people and animals. The addressable markets for their main products or services are outlined below:
Human Health Segment
-
Mytesi (Crofelemer) for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy:
A specific addressable market size in USD for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy was not identified in the search results. However, the broader global antidiarrheal drug market was valued at USD 102.15 billion in 2024 and is projected to reach USD 145.67 billion by 2031. Another estimate places the global antidiarrheals market at USD 3.8 billion in 2025, projected to grow to USD 6.2 billion by 2034. -
Crofelemer for cancer therapy-related diarrhea (CTD):
The chemotherapy-induced diarrhea market across the seven major markets (United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan) was approximately USD 80 million in 2023. The United States alone accounted for about USD 40 million of this market in 2023. This market reached USD 89.2 million across the top 7 markets in 2024 and is expected to reach USD 164.6 million by 2035. -
Crofelemer for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders (CDD):
null -
Crofelemer for adult and pediatric patients for short bowel syndrome with intestinal failure (SBS-IF):
The global short bowel syndrome market size was valued at USD 1.65 billion in 2025 and is projected to grow to USD 2.7 billion by 2034. The market in the seven major markets is expected to grow from USD 2.45 billion in 2025 to USD 3.99 billion in 2034. North America held the largest share of the global SBS market at 75.87% in 2025. The U.S. market alone for SBS was USD 1.16 billion in 2024 and is projected to reach USD 2.09 billion by 2032. -
Crofelemer for supportive care for diarrhea relief in inflammatory bowel diseases (IBD):
The global inflammatory bowel disease treatment market was valued at USD 26.6 billion in 2024 and is expected to grow to USD 47.3 billion by 2034. Another estimate places the global IBD treatment market size at USD 20.74 billion in 2023, projected to reach USD 27.73 billion by 2030. North America dominated this market, holding a 57.59% share in 2023. The combined global market for irritable bowel syndrome (IBS) and IBD therapeutics was valued at USD 30.4 billion in 2024 and is expected to reach USD 52.6 billion by 2030. -
Crofelemer for diarrhea-predominant irritable bowel syndrome (IBS-D):
The global irritable bowel syndrome (IBS) market size is forecasted to be USD 7.19 billion in 2025, with an expectation to reach USD 24.96 billion by 2034. The IBS-D segment represented the largest portion of the total IBS treatment utilization globally, accounting for approximately 41% or 49.8% in 2024. The IBS-D segment led the market in 2023 with a 43.8% revenue share. The global IBS treatment market was valued at USD 3.05 billion in 2023 and is expected to reach USD 6.46 billion by 2032. -
Crofelemer for idiopathic/functional diarrhea:
A specific addressable market size in USD solely for idiopathic/functional diarrhea was not identified. However, the global functional bowel disorder agents market was valued at USD 2.071 billion in 2021 and is expected to reach USD 3.25 billion by 2029. This market includes treatments for IBS, chronic bloating, and constipation in addition to diarrhea. -
Lechlemer for cholera:
The global cholera treatment market was valued at USD 149.36 million in 2024 and is expected to reach USD 278.51 million by 2032. Another projection estimates the global cholera treatment market size to reach USD 252.5 million by 2030. The global cholera vaccine market, a related segment, was valued at USD 93.9 million in 2024 and is projected to reach USD 163.4 million by 2030.
Animal Health Segment
-
Canalevia for chemotherapy-induced diarrhea (CID) in dogs:
Canalevia-CA1 is conditionally approved for CID in dogs in the U.S. While a specific market size in USD for canine chemotherapy-induced diarrhea was not found, there were approximately 90 million dogs in the U.S. in 2024. -
Canalevia for exercise-induced diarrhea (EID) in dogs:
null. Diarrhea affects a significant portion of working and sporting dogs, with a reported prevalence of 7.5–36% in long-distance racing sled dogs. In one study, diarrhea occurred in 36% of dogs during racing.
AI Analysis | Feedback
Jaguar Health, Inc. (JAGX) is anticipated to drive future revenue growth over the next two to three years through several strategic initiatives centered on its key compound, crofelemer, across both human and animal health segments.
- Expansion of Crofelemer (Mytesi) for Cancer Therapy-Related Diarrhea (CTD): A significant driver is the potential approval and commercialization of crofelemer for the preventative treatment of cancer therapy-related diarrhea (CTD), also referred to as chemotherapy-induced overactive bowel (CIOB). Although the primary endpoint of the Phase 3 OnTarget trial was not met in a broad patient population, subgroup analyses revealed clinically meaningful benefits in patients with breast and respiratory cancers, including lung cancer, which represent a large portion of cancer patients. Jaguar Health is pursuing discussions with the FDA to identify an efficient regulatory pathway for this indication, with NDA filings targeted by the end of 2026. The market for chemotherapy-induced diarrhea is projected to expand significantly, from approximately $80 million in 2023 to $164.6 million by 2035 across the seven major markets.
- Advancement of Crofelemer for Orphan Drug Indications (Short Bowel Syndrome (SBS) and Microvillus Inclusion Disease (MVID)): Jaguar Health is actively developing crofelemer for rare disease indications such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). Investigator-initiated proof-of-concept studies have yielded promising early results, and the company is pursuing expedited review pathways with regulatory authorities in both the United States and Europe. Published data from these ongoing clinical investigations could facilitate reimbursed early patient access to crofelemer, potentially within the 2-3 year timeframe. The global SBS market alone was valued at over $568 million in 2019 and is expected to reach $4.6 billion by 2027, highlighting a substantial unmet medical need.
- Full Commercialization and Expanded Approval of Canalevia-CA1 in Animal Health: Canalevia-CA1 (crofelemer) for chemotherapy-induced diarrhea (CID) in dogs, which currently holds conditional FDA approval, is another key revenue driver. The conditional approval was renewed through December 21, 2026, and a confirmatory effectiveness trial is underway, expected to conclude in February 2026, aiming for full FDA approval. Canalevia-CA1 is already available through major U.S. veterinary distributors, including Chewy. Furthermore, Jaguar Health is pursuing EMA engagement for potential approval in European dogs and has established a licensing agreement for the Chinese market, indicating further geographical expansion opportunities.
- Strategic Partnerships and Licensing Agreements: Jaguar Health continues to leverage strategic partnerships and licensing deals to secure non-dilutive funding and broaden the market reach of its products. Recent examples include agreements like the Future Pak deal for Mytesi and Canalevia-CA1, which can provide capital and support commercialization efforts. The company also entered an exclusive license and commercialization agreement with SynWorld Technologies for Canalevia in China, involving license fees and profit-sharing. These collaborations for both existing and pipeline products, such as the stated goal to partner NP300 for the general canine diarrhea market, are expected to contribute to future revenue growth by expanding access and commercial capabilities.
AI Analysis | Feedback
Share Issuance
- Jaguar Health completed an At-the-Market (ATM) financing program in 2024, raising approximately $30.8 million, and had previously upsized the program by $15.3 million in April 2021 for potential future financing needs.
- In April 2025, the company finalized a private placement, securing approximately $3.448 million through the issuance of convertible promissory notes and unregistered warrants.
- A reverse stock split at a ratio of 1-for-25 was effected on March 24, 2025, to support compliance with Nasdaq's listing standards and aim for a more attractive share price for institutional investors.
Inbound Investments
- In January 2026, Jaguar Health entered into a U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1, receiving $16 million in non-dilutive capital upon closing, with an additional $2 million contingent and up to $20 million in future milestone payments.
- An additional $3 million payment was received from Future Pak in March 2026 following Jaguar's termination of a buy-back provision in the licensing agreement.
- Napo Therapeutics S.p.A., a subsidiary of Jaguar Health, successfully closed an initial private placement financing round in February 2023 at a fully diluted valuation of approximately €55 million, with plans to raise up to €7 million to support clinical development.
Capital Expenditures
- Jaguar Health's historical capital expenditures were minimal, reported as $0 million in 2020, $0 million in 2021, $2 million in 2022, $0 million in 2023, and $0 million in 2024.
- The company's projected capital expenditures are $0 million for 2025 and $1 million annually from 2026 to 2029.
- Proceeds from a May 2025 direct offering were earmarked for general corporate purposes, including capital expenditures.
Peer Outperformance in Biotechnology
JAGX has trailed 100% of its 361 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that JAGX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
0%
of 450 industry peers · -99.8% return
3Y
0%
of 396 industry peers · -100.0% return
5Y
0%
of 361 industry peers · -100.0% return
No Biotechnology peer with a comparable growth profile has beaten JAGX by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is JAGX's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 9.3% | 56.9% | 98.5% | CAH 480% · MCK 390% · COR 186% |
| Health Care Services | 20 | 37.1% | 44.9% | 12.4% | HIMS 255% · RDNT 136% · DGX 89% |
| Managed Health Care | 8 | 34.3% | -1.3% | -3.6% | OSCR 76% · HQY 55% · ELV 4% |
| Health Care Facilities | 25 | 12.3% | 15.9% | -5.4% | THC 281% · NHC 236% · EHC 182% |
| Health Care Equipment | 50 | -0.4% | 12.2% | -17.8% | GKOS 420% · UFPT 360% · PLSE 148% |
| Pharmaceuticals | 61 | -13.5% | 9.4% | -34.9% | LQDA 1102% · KNSA 788% · LLY 482% |
| Health Care Supplies | 11 | 16.7% | 1.0% | -39.9% | LNTH 329% · HAE 74% · MMSI 28% |
| Life Sciences Tools & Services | 107 | -5.3% | -0.6% | -66.4% | NTRA 262% · AXGN 225% · MEDP 188% |
| Biotechnology ← | 362 | -24.8% | -26.7% | -80.9% | DNTH 1187% · ELVN 1129% · TRVI 1054% |
| Health Care Technology | 21 | -24.4% | -48.5% | -82.4% | VEEV -1% · DOCS -53% |
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 380.69 |
| Mkt Cap | 211.9 |
| Rev LTM | 30,987 |
| Op Inc LTM | 11,426 |
| FCF LTM | 10,175 |
| FCF 3Y Avg | 8,754 |
| CFO LTM | 12,478 |
| CFO 3Y Avg | 10,312 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.1% |
| Rev Chg Q | 10.2% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 39.5% |
| Op Inc Chg 3Y Avg | 11.2% |
| Op Mgn LTM | 33.9% |
| Op Mgn 3Y Avg | 27.5% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | 32.8% |
| CFO/Rev 3Y Avg | 31.6% |
| FCF/Rev LTM | 28.3% |
| FCF/Rev 3Y Avg | 24.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Human Health | 11 | 11 | 10 | 12 | 4 |
| Animal Health | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 10 | 12 | 4 |
| $ Mil | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Animal Health | -20 | -30 | -28 | -24 | -19 |
| Human Health | -22 | -18 | -24 | -10 | -19 |
| Total | -42 | -48 | -53 | -34 | -39 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Animal Health | 186 | 175 | 153 | 129 | 116 |
| Human Health | 28 | 44 | 42 | 41 | 42 |
| Investment in subsidiary | -29 | -29 | -29 | -29 | -29 |
| Intercompany loan | -146 | -136 | -115 | -93 | -75 |
| Total | 38 | 53 | 51 | 47 | 53 |
Price Behavior
Price Behavior
| Market Price | $1.62 | |
| First Trading Date | 05/13/2015 | |
| Distance from 52W High | -99.8% | |
| 50 Days | 200 Days | |
| DMA Price | $6.46 | $120.09 |
| DMA Trend | down | down |
| Distance from DMA | -74.9% | -98.7% |
| 3M | 1YR | |
| Volatility | 2,403.7% | 1,208.5% |
| Downside Capture | 1056.21 | 689.45 |
| Upside Capture | -209.91 | -146.70 |
| Correlation (S&P 500) | 2.2% | 3.4% |
JAGX Betas & Captures as of 9/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 12.13 | 1.54 | 3.37 | 0.95 | 2.73 | 1.74 |
| Up Beta | -11.86 | -2.37 | 0.48 | 0.55 | 1.57 | 1.27 |
| Down Beta | 611.71 | 335.00 | 131.24 | 46.36 | 23.62 | 6.36 |
| Up Capture | -428% | -252% | -225% | -109% | -43% | -3% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 5 | 12 | 17 | 43 | 93 | 294 |
| Down Capture | 821% | 597% | 544% | 355% | 194% | 113% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 17 | 28 | 44 | 79 | 152 | 435 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JAGX | |
|---|---|---|---|---|
| JAGX | -99.9% | 1,208.5% | 0.42 | - |
| Sector ETF (XLV) | 30.2% | 16.4% | 1.41 | 3.9% |
| Equity (SPY) | 10.9% | 12.8% | 0.52 | 3.3% |
| Gold (GLD) | -2.0% | 28.6% | -0.08 | 3.7% |
| Commodities (DBC) | 48.2% | 20.6% | 1.79 | -5.3% |
| Real Estate (VNQ) | 10.2% | 13.7% | 0.45 | 1.4% |
| Bitcoin (BTCUSD) | -30.3% | 43.5% | -0.71 | 2.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JAGX | |
|---|---|---|---|---|
| JAGX | -97.3% | 553.0% | -0.10 | - |
| Sector ETF (XLV) | 8.7% | 15.3% | 0.37 | 4.2% |
| Equity (SPY) | 12.2% | 17.1% | 0.53 | 5.0% |
| Gold (GLD) | 16.2% | 19.0% | 0.68 | 2.9% |
| Commodities (DBC) | 9.2% | 19.5% | 0.35 | -1.8% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 3.6% |
| Bitcoin (BTCUSD) | 4.8% | 51.6% | 0.28 | 2.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with JAGX | |
|---|---|---|---|---|
| JAGX | -90.1% | 448.3% | -0.08 | - |
| Sector ETF (XLV) | 12.0% | 16.8% | 0.59 | 3.5% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 4.6% |
| Gold (GLD) | 11.4% | 16.5% | 0.56 | 2.9% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | -0.0% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.21 | 2.4% |
| Bitcoin (BTCUSD) | 61.7% | 66.2% | 1.01 | 3.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 10/5/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/19/2026 | -5.5% | -0.5% | -80.5% |
| 5/20/2026 | -5.4% | -10.4% | -28.9% |
| 5/15/2025 | 6.9% | -17.6% | -37.3% |
| 11/13/2024 | -9.4% | -11.1% | -10.5% |
| 8/13/2024 | -10.8% | 3.3% | -5.8% |
| 8/14/2023 | -6.5% | -12.6% | -40.7% |
| 5/15/2023 | -22.6% | -32.3% | -30.6% |
| 3/27/2023 | -8.0% | -44.5% | -57.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 3 | 5 | 3 |
| # Negative | 12 | 10 | 12 |
| Median Positive | 6.9% | 4.7% | 41.1% |
| Median Negative | -5.9% | -11.8% | -24.8% |
| Max Positive | 10.0% | 52.8% | 96.7% |
| Max Negative | -22.6% | -44.5% | -80.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/19/2026 | -5.5% | -0.5% | -80.5% |
| 5/20/2026 | -5.4% | -10.4% | -28.9% |
| 5/15/2025 | 6.9% | -17.6% | -37.3% |
| 11/13/2024 | -9.4% | -11.1% | -10.5% |
| 8/13/2024 | -10.8% | 3.3% | -5.8% |
| 8/14/2023 | -6.5% | -12.6% | -40.7% |
| 5/15/2023 | -22.6% | -32.3% | -30.6% |
| 3/27/2023 | -8.0% | -44.5% | -57.8% |
| 11/14/2022 | -6.3% | -13.3% | -19.9% |
| 5/10/2022 | -3.3% | -6.2% | -15.2% |
| 3/11/2022 | -3.3% | 52.8% | 41.1% |
| 11/18/2021 | 4.1% | -4.8% | -20.7% |
| 5/17/2021 | -3.1% | 4.7% | 33.9% |
| 3/31/2021 | 10.0% | 7.8% | -16.1% |
| 11/16/2020 | -3.5% | 2.0% | 96.7% |
| SUMMARY STATS | |||
| # Positive | 3 | 5 | 3 |
| # Negative | 12 | 10 | 12 |
| Median Positive | 6.9% | 4.7% | 41.1% |
| Median Negative | -5.9% | -11.8% | -24.8% |
| Max Positive | 10.0% | 52.8% | 96.7% |
| Max Negative | -22.6% | -44.5% | -80.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/19/2026 | 10-Q |
| 03/31/2026 | 05/20/2026 | 10-Q |
| 12/31/2025 | 04/07/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/24/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/19/2026 | 10-Q |
| 03/31/2026 | 05/20/2026 | 10-Q |
| 12/31/2025 | 04/07/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/24/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/22/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/11/2022 | 10-K |
| 09/30/2021 | 11/17/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/17/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/15/2020 | 10-Q |
| 12/31/2019 | 04/03/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/30/2026